RESEARCH MATERIAL — NO ESTABLISHED SYSTEMIC HUMAN USE
GHK-Cu — scientific overview
GHK-Cu is the copper complex of glycyl-L-histidyl-L-lysine.
Mechanistic and preclinical studies describe regenerative and extracellular-matrix effects.
Human clinical evidence remains limited.
1. Scientific profile
|
Parameter |
Classification |
|
Molecule |
Glycyl-L-histidyl-L-lysine-Cu²⁺ |
|
Class |
Copper-binding tripeptide |
|
Evidence |
Predominantly mechanistic / preclinical |
|
Drug status |
No established systemic approval |
2. Biological research context
GHK-Cu is not defined by a single pharmacological receptor.
|
Area |
Observation |
Context |
|
Cu²⁺
|
Copper binding
|
GHK forms a stable copper complex. |
|
ECM
|
Matrix regulation
|
Cell and preclinical data describe collagen and glycosaminoglycan effects. |
|
Repair
|
Tissue repair
|
Inflammation, migration and wound healing are studied in several models. |
3. Human evidence
Human evidence remains limited relative to the preclinical literature.
What is actually supported?
CO₂-laser trial
13 participants; no significant objective differences in erythema, wrinkles or skin quality.
Subjective outcome
Patient satisfaction with skin quality was higher in the GHK-Cu group.
2025 review
Highlighted a surprising absence of robust clinical studies.
2026 research
New hydrogel research remains preclinical rather than human efficacy evidence.
4. Current research status
Mechanistic
Broad cell and preclinical literature
Human
Limited, predominantly topical
Systemic PK
Not adequately established
5. Research-material distinction
Preclinical mechanisms and cosmetic literature do not establish clinical efficacy, systemic safety or properties of a specific research batch.
